

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GenFleet Therapeutics (Shanghai) Inc.

勁方醫藥科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2595)

VOLUNTARY ANNOUNCEMENT

Disclosure Arrangements for Clinical Data from Studies of GFH375 and GFH276

This announcement is made by GenFleet Therapeutics (Shanghai) Inc. (the “**Company**” or “**GenFleet**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

Disclosure Arrangement for GFH375's Clinical Data

The Company will release preliminary data from the study evaluating GFH375, the Company's investigational KRAS G12D inhibitor, in combination with cetuximab for the treatment of KRAS G12D-mutant solid tumors via an online investor call on October 15, 2026.

The Company's overseas partner Verastem Oncology (“**Verastem**”) will introduce the overseas clinical progress of GFH375/VS-7375 via an online investor call on October 14, 2026.

Disclosure Arrangement for GFH276's Clinical Data

The preliminary clinical data from the study of GFH276, the Company's investigational Pan RAS inhibitor, as monotherapy in patients with RAS-mutant solid tumors have been selected in a late-breaking abstract (LBA), at the 2026 annual meeting of the European Society for Medical Oncology (ESMO) to be held in Madrid.

Abstract title: (LBA33) Safety and efficacy of GFH276 monotherapy in previously treated RAS-mutated advanced solid tumors

Session: Local time 8:30-10:00 a.m., October 25, 2026 (Development Therapeutic Session)

The Company will hold an online investor call on October 25, 2026, to further interpret the data from the on-site oral presentation of GFH276.

About GFH375/VS-7375 and GFH276

GenFleet entered into a license and early-stage development collaboration with Verastem to advance three novel oncology discovery products related to RAS/MAPK pathway-driven cancers. The collaboration provides Verastem with an exclusive option to obtain a license for each of the three products in the collaboration after the successful completion of pre-determined milestones in a Phase I trial. Verastem selected GFH375/VS-7375 as its lead program from the collaboration in December 2023 and the license for GFH375 that was exercised in January 2025 is the first one from this collaboration. The licenses would give Verastem development and commercialization rights outside of China while GenFleet would retain rights within China.

GFH276 is an oral novel small-molecule Pan RAS (ON) inhibitor employing the tri-complex mechanism (Cyp A-GFH276-RAS) to target active RAS proteins of most wild/mutant subtypes, including most commonly found KRAS mutant (G12C, G12D, G12V, etc.) proteins, as well as NRAS and HRAS isoforms.

Forward-looking Statements

Specific information in this announcement may contain or constitute forward-looking words that are not historical facts. They can be identified by using forward-looking terminology, such as “predict”, “believe”, “plan”, “forecast”, “expect”, “will”, “may”, “should” and other words of similar meanings. Based on the management’s current beliefs, plans, estimates and expectations of the Company’s operation and market trends subject to changes beyond control, the forward-looking terminology reflects the Company’s beliefs, plans, estimates and expectations of future development. Actual outcome in the future may differ significantly from forward-looking words owing to market, policy, and R&D uncertainties, among others. Subject to the above-mentioned uncertainties, the Company makes no expressed or implied guarantee as to the accuracy, completeness or feasibility of this presentation, and you are cautioned not to solely rely on such forward-looking words. Neither the company nor any of its directors, officers, employees, shareholders, agents, related parties, consultants or representatives will be liable to you or any other person for consequences resulting from using this presentation. Investors are advised to exercise due diligence with reference to the company’s official disclosures for decision-making.

GLOSSARY OF TECHNICAL TERMS

“CypA”

Cyclophilin A

“ESMO”

European Society for Medical Oncology

“Pan RAS (ON) ”	active forms of RAS proteins across wild-type and mutant variants
“HRAS”	Harvey RAS, a member of the RAS family proteins
“KRAS”	Kirsten RAS, a member of the RAS family of proteins
“LBA”	late-breaking abstract
“MAPK”	mitogen-activated protein kinase, a family of proteins involved in transmitting signals from cell surface receptors to the nucleus
“NRAS”	neuroblastoma RAS, a member of the RAS family proteins
“RAS”	rat sarcoma, a family of proteins that are critical regulators of cellular signaling pathways; it primarily includes HRAS, KRAS, and NRAS

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market GFH375 and GFH276 successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
GenFleet Therapeutics (Shanghai) Inc.
Dr. Qiang LU
Chairman and Executive Director

Hong Kong, September 23, 2026

As at the date of this announcement, the Board of the Company comprises: (i) Dr. Qiang LU, Dr. Jiong LAN and Ms. ZHANG Wei as executive directors; (ii) Mr. ZHU Jingyang and Ms. TAO Sha as non-executive directors; and (iii) Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo as independent non-executive directors